Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
 
Advanced search:
Enter Search Keyword
 
Filter your search by:
Industry
Country
Publish date
Search By Price Range
From:$
    To:$
 
GBI Research
Results 1-10 of 220  1 2 3 >  Last › Sort By :
Title Date Price
Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
By GBI Research
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion ...Read More
Apr 2017 $4995.00
Breast Cancer Therapeutics in Southeast Asia Markets to 2022-Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market
By GBI Research
 Description Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to o ...Read More
Apr 2017 $4995.00
Pharmaceutical Lifecycle Management Strategies in 2017
By GBI Research
Description GBI Research’s latest report Pharmaceutical Lifecycle Management Strategies in 2017 provides a comprehensive assessment of product lifecycle (LCM) management strategies that are be ...Read More
Apr 2017 $2995.00
Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of w ...Read More
Mar 2017 $3995.00
Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design
By GBI Research
GBI Research’s latest report Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through Risk Management and Quality by Design provides an in-depth assessment of ...Read More
Mar 2017 $2995.00
Frontier Pharma: Fatty Liver Disease- High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products
By GBI Research
Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and f ...Read More
Mar 2017 $6995.00
Back to Report Store Home Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Description Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Mar 2017 $3995.00
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market
By GBI Research
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease MarketSummaryThe respiratory therapy area cons ...Read More
Mar 2017 $4995.00
Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation
By GBI Research
Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class InnovationSummaryHead and neck squamous cell carcinoma is the sixth most common cance ...Read More
Mar 2017 $6995.00
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
By GBI Research
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the MarketSummaryNon-Small Cell Lung Cancer (NSCLC) is ...Read More
Mar 2017 $4995.00
Results 1-10 of 220  1 2 3 >  Last ›

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z